


# **Biomarkers of Industrial and Environmental Exposure to 1,3-Butadiene**

**Natalia Tretyakova**  
**University of Minnesota Cancer Center and**  
**The Department of Medicinal Chemistry**

*Slides Prepared for the 2014 Symposium on Understanding the Health Risks of Lower Olefins*

**November 5, 2014**

# Central dogma of chemical carcinogenesis





Adapted from Tsunehiro Oyama et al. *Frontiers in Bioscience*, 9, 1967-1976, 2004, Hecht, S. S. J. Natl. Cancer Inst. 91, 1194-1210

# Sources of human exposure to BD



**Occupational exposure  
(0.5-1.0 ppm)**



**~ 0.15 ppb  
Wood burning  
forest fires**




**~20-75 µg  
per cigarette**




**Automobile exhaust  
~0.1-10 ppb in urban air**

# Metabolism of 1,3-Butadiene



## Mutagenicity



S Kotapati et al. Chem. Res. Toxicol. 2011, 24, 1516–1526; Van Sittert et al. Toxicol. Sci. 2000, 56, 189–202; S Kotapati et al. Carcinogenesis. 2014;35(6):1371-8.

# Interspecies differences in sensitivity to BD-mediated cancer



- Laboratory mice develop tumors following exposure to 6.25 ppm BD, while rats require ~ 200-fold higher concentrations.
- This may be explained by a more efficient formation of DEB in mice:
  - Higher amounts of DEB are detected in blood of BD-exposed mice.
- Greater amounts of DEB-globin adducts are found in mice.

Filser et al. *Chem. Biol. Interact.* 166, 93-103 (2007)

Boysen et al. *Chem. Biol. Interact.* 166, 84-92 (2007)

# What determines individual susceptibility to BD?

Individuals and ethnic groups may differ in respect to metabolic activation and deactivation of BD, leading to an differences in formation of DNA-reactive BD intermediates/ modified risk.



# Genetic polymorphisms in BD Metabolizing Genes

Protein	Variant	Changes to Genotype/Phenotype
GSTT1 <sup>12-14</sup>	rs11550605	A>C → Thr104Pro; decreased protein expression
	rs199521920	C>T in exon 2 → Asp43Asn; decreased protein expression
		C>T in exon 2 → Thr65Met; decreased protein expression
CYP2E1 <sup>15-16</sup>	rs6413432	A>T in intron 6; introduces Dra1 site
	rs3813867	G>C in 5' upstream region; introduces Pst1 site
	rs2031920	C>T in 5' upstream region; removes RsaI site
EPHX1 <sup>8</sup>	rs1051740	T>C in exon 3 → Tyr113His; decreased protein activity
	rs2234922	A>G in exon 4 → His139Arg; increased protein activity

## Ethnic differences in incidence of genetic polymorphisms in xenobiotic-metabolizing gene (percentages)

	GSTM1-1 Null	GSTT1-1 Null	Slow EH	Fast EH	Low CYP2E1 Activity	Low CYP2A6 Activity
European American	52 <sup>7</sup>	14.7 <sup>7</sup>	27.9 <sup>8</sup>	19.1 <sup>8</sup>	1 <sup>7</sup>	21.5 <sup>9</sup>
African American	27 <sup>7</sup>	21.8 <sup>7</sup>	20.8 <sup>8</sup>	28.9 <sup>8</sup>	4 <sup>7</sup>	2.5 <sup>9</sup>
Japanese	48.6 <sup>7</sup>	44.3 <sup>11</sup>	44 <sup>10</sup>	14 <sup>10</sup>	19.3 <sup>7</sup>	48 <sup>9</sup>

Wormhoudt, L. W. et al. *Crit. Rev. Toxicol.* **1999**, 29, 59-124.

London, S. J. et al. *Lung Cancer.* **2000**, 28, 147-155.

Fernandez-Salguero, P. et al. *Am. J. Hum. Gent.* **1995**, 57, 651-660.


Yoshikawa, M. et al. *Int. J. Mol. Med.* **2000**, 5, 49-53.



# Goals of this work

- Develop biomarkers of human exposure to BD (urinary metabolites, DNA adducts)
- Evaluate BD exposure in general population, smokers, and occupationally exposed workers
- Investigate ethnic and individual variability in BD metabolism/DNA adduct formation.

# Urinary Metabolites of 1,3-Butadiene



**GST:** Glutathione-S-transferase,  
**ADH:** Alcohol dehydrogenase

**Metabolic Ratio = MHBMA/(MHBMA + DHBMA)**

- Inversely proportional to epoxide hydrolase activity
- Higher ratio suggests higher risk

# Mass Spectrometry Based Quantitation of Urinary BD-Mercapturic Acids

Urine Aliquot (100  $\mu$ L)




Add internal standard  
(60 ng each of deuterium labeled MA)



Solid Phase Extraction  
(Isolute ENV+ 1ml/50 mg)





HPLC- ESI<sup>-</sup>- MS/MS analysis




**MHBMA and DHBMA:** Varian Pursuit 3 Diphenyl column 2.1 x 150  
**THBMA and *bis*-BDMA:** SIELC Primesep D 2.1 x 100

# HPLC-MS/MS method for MHBMA and DHBMA




Range (ng/ml)	LOD (ng/ml)	LOQ (ng/ml)	Intra-day precision (%)	Inter-day Precision (%)	Accuracy (%)	Extraction recovery (%)
5-16,000	1	5	0.88	1.17	98.04	46

# Representative HPLC-ESI-MS/MS Traces for MHBMA and DHBMA in Human Urine





# The levels of all BD-mercapturic acids in rat urine increase linearly with BD exposure





Rat urine samples provided by Dr. Vernon Walker  
(University of Vermont)





# DEB-derived *bis*-BDMA was detected in the urine of F344 rats exposed to BD, but not in humans



## Occupationally exposed worker (2 ppm)






# First detection of THBMA in humans




**SMOKER**

**NON-SMOKER**





# Association of urinary BD-mercapturic acids with exposure



MHBMA is associated with BD exposure, but the correlation is weak for DHBMA and THBMA






# BD-urinary acids in urine of occupationally exposed workers

Czech cohort (Albertini et al. *Chemico-Biological Int.* 166 (2007) 63-77)


		Concentrations (ng/ml)				
	N	BD exposure (mg/m <sup>3</sup> )	MHBMA	DHBMA	THBMA	Metabolic Ratio
<b>Males</b>						
Controls	21	0.007 ± 0.005	9.9 ± 11	1480 ± 968	58 ± 33	0.007 ± 0.008
Exposed	16	0.68 ± 0.41	96 ± 111	3136 ± 2560	139 ± 104	0.027 ± 0.026
<b>Females</b>						
Controls	19	0.007 ± 0.005	3.1 ± 4.8	561.2 ± 531.5	24.2 ± 16.6	0.006 ± 0.007
Exposed	16	0.32 ± 0.34	8.3 ± 8.1	716.1 ± 830.7	47.4 ± 70.9	0.017 ± 0.012

- Significantly higher concentrations of BD-mercapturic acids in urine of exposed workers
- Greater increase in males vs females
- Large amounts of BD-mercapturic acids detected in unexposed controls
- No bis-BDMA detected in human urine

# Relative concentrations of BD-mercapturic acids in urine of BD-exposed rats and in human smoker urine




**Rats (62.5 ppm BD)**



**Humans (1- 2 ppm BD)**

- Humans excrete a lot of DHBMA
- bis-BDMA is undetectable in human urine

# Ethnic differences in excretion of urinary BD-mercapturic acids




MHBMA			
Group	N	Mean ± SD (nmol/mg)	P-value
Afr. Am.	346	10.87 ± 8.3	0.0002
Jap. Am.	380	9.64 ± 19.8	< 0.0001
Eur. Am.	426	14.3 ± 12.6	-

DHBMA			
Group	N	Mean ± SD (nmol/mg)	P-value
Afr. Am.	346	611.85 ± 436.6	0.0142
Jap. Am.	380	806 ± 974.6	0.7425
Eur. Am.	426	725.22 ± 703.5	-



# GWAS Shows an Association Between MHBMA Excretion and SNPs on Chromosome 22

Manhattan-plot -- MHBMA\_rk




19 SNPs with statistical significance on chromosome 22, mostly glutathione S-transferases  
**GSTT1** = glutathione S-transferase theta 1  
**GSTT2** = glutathione S-transferase theta 2

# DHB-Lys: a Novel DEB-Specific Urinary Biomarker




N<sup>6</sup>,N<sup>6</sup>-(2,3-dihydroxybutan-1,4-diyl)-lysine  
(DHB-Lys)

# Detection of DHB-Lys in Smoker's Urine



# 1,3-Butadiene- Induced DNA adducts: Biomarkers of risk




Exp Pathol. 1989;37(1-4):108-13; Atmospheric Environment 2006 40, 170–181; Chem Biol Interact 2007 166(1-3):44-51; Chem. Res. Toxicol. 2007, 20, 839-847; Chem. Res. Toxicol. 2008, 21, 1163–1170; Chem. Res. Toxicol. 2010, 23, 808–812; Chem. Res. Toxicol. 2013, 26, 1486–1497.




# Studies of BD DNA adducts *in vivo*: Demands for increased MS sensitivity/selectivity

## Analytical challenges:

- Limited DNA sample
- Artifacts and contamination
- Accurate quantitation is required to detect small differences between groups
- Endogenous exposome



# Sample preparation procedure for the quantitation of N7-guanine DNA adducts



## DNA in solution

Blood WBCs/buffycoat, various tissue cells



← **Stable isotope labeled internal standard**

## Neutral Thermal Hydrolysis and Ultra-filtration




## DNA adduct enrichment


Solid phase Extraction (SPE) and/or  
Offline HPLC fractionation



## Isotope dilution MS analysis




$$\text{Amount}_{\text{analyte}} = \frac{\text{Area}_{\text{analyte}}}{\text{Area}_{\text{Internal Standard}}} \times \text{Amount}_{\text{Internal Standard}}$$




# HPLC-ESI<sup>+</sup>-HRMS/MS analysis of N7-THBG in leukocyte DNA of a smoker and an occupationally BD exposed worker

Sample matrix	LOQ	Range	Accuracy	Intra/interday precision	DEB treated HT1080 cells (1-100 μM)
Control DNA from HT1080 cells	1.0 fmol/150 μg of DNA (2 adducts/10 <sup>9</sup> nucleotides)	1.0 - 50 fmol (Y = 1.059 X, R <sup>2</sup> = 0.9989)	92.3 ± 6.7 (N = 5)	%CV < 13%	y = 9.4252x + 2.4797 R <sup>2</sup> = 1 <b>(Endogenous levels: 2.03 fmol/150 μg DNA)</b>

## Occupationally exposed worker





## Smoker




# N7-THBG concentrations in leukocyte DNA of BD exposed humans



**N7-THBG in Smokers vs Non Smokers**  
(N=13, Two sample t-Test, P = 0.60)



**BD Occupational Exposure N7-THBG**  
**Levels (N=10, Two sample t-Test, P = 0.0001)**




# Isotope dilution NanoLC/ESI<sup>+</sup>-HRMS<sup>3</sup> analysis of EB-GII adducts




# EB-GII quantitation in liver of BD-exposed rats

Sample matrix	LOD	LOQ	Range	Accuracy	Intra/interday precision
Nonsmoker Blood DNA	0.02 fmol/150 $\mu$ g DNA	0.2 fmol/150 $\mu$ g of DNA (0.4 adducts/ $10^9$ nucleotides)	0.2 - 10 fmol (Y = 0.905 X, R <sup>2</sup> = 0.995)	92.9 $\pm$ 7.1 (N=9)	%CV < 8%




**EB-GII formation in liver tissue DNA of F344 rats exposed to BD (0.5, 1, 1.5 ppm) for 2 weeks (5 days per week)**






**EB-GII adducts in liver DNA of a F344 rat exposed to 1.0 ppm BD by inhalation for 2 weeks**

# Attempted quantitation of EB-GII in blood leukocyte DNA of smokers and nonsmokers



**EB-GII levels are either equal or below the Limit of quantitation of the method (0.2 fmol in 150µg of DNA)!**

# EB-GII *in vivo* half life in liver tissue DNA of F344 rats exposed to 1250 ppm BD



EB-GII


$t_{1/2} = 2.20 \pm 0.12$  days

Hydrolysis/DNA adduct repair

Urinary excretion!




# Quantitation of urinary EB-GII adducts




Method validation results	
Sample matrix	Nonsmoker urine (200 $\mu\text{L}$ )
LOD	0.05 fmol
LOQ	0.1 fmol
Range	0.1 - 10 fmol ( $Y = 1.0042 X$ , $R^2 = 0.999$ )
Accuracy	$109.8 \pm 10.4$ (N=5)
Intra/interday precision	%CV < 13%



**EBG-II urinary levels in male and female F344 rats exposed to 0, 62.5 and 200 ppm**




# NanoLC/ESI<sup>+</sup>-HRMS<sup>3</sup> analysis of EB-GII in urine of smokers and occupationally exposed workers



# Urinary EB-GII concentrations in occupational BD exposed workers vs administrative controls, nonsmokers vs smokers







# Ethnic/racial differences in the formation of butadiene-DNA adducts upon exposure to BD



# Racial/ethnic differences in urinary EB-GII excretion

## Hypothesis:



Genotyping in progress to identify the origins of ethnic differences

# Conclusions

- 1. Several new biomarkers of exposure to BD have been developed and applied to smokers, occupationally exposed workers, and controls.**
- 2. Urinary BD-mercapturic acids and BD-DNA adducts are associated with exposure.**
- 3. Interspecies and ethnic/interindividual differences in BD metabolism have been revealed.**
- 4. “Unexposed” individuals contain significant numbers of BD-DNA adducts and excrete BD-mercapturic acids.**

# Future Directions

- 1. Evaluate DHB-Lys as a novel DEB-specific urinary biomarker.**
- 2. Identify the origins of endogenous THBMA, DHBMA, THB-Gua, and EB-Gua.**
- 3. Quantify DEB-derived metabolites and DNA adducts in rats, mice, and humans exposed to sub-ppm concentrations of BD.**

# Acknowledgements

**Students: Melissa Goggin, Srikanth Kotapati, Dewakar Sangaraju, Emily Boldry**



**Animal Tissues: James A. Swenberg (UNC), Vernon Walker (Univ. of Vermont)**

**Human urine and blood samples: Univ. of Minnesota Biorepository, American Chemistry Council Olefins Panel and Richard J. Albertini (University of Vermont)**

**Special thanks to: Kimberly Wise (American Chemistry Council Olefins Panel) Richard J. Albertini (University of Vermont)**

**Funding:**

**American Chemistry Council, NIH P01 CA-138338, R01-CA-100670**